Consumer Perceptions, Attitudes, and Intentions by Biosimilar Disclosure Characteristics
| Control (no definition) | Kesterin is a Biosimilar | Kesterin is a Biosimilar + Effective | Kesterin is a Biosimilar + Effective + Same Sources | Kesterin is a Biosimilar + Effective + Same Sources + Dosage and Administration | Names the Reference Drug Mytrozen in Definition | Does Not Name Reference Drug in Definition | |
|---|---|---|---|---|---|---|---|
| Perceived benefit/efficacy | |||||||
| Benefit likelihood | 3.93 (1.39) | 3.84 (1.40) | 4.04 (1.22) | 4.13 (1.34) | 4.38 (1.16) | 4.05 (1.23) | 4.32 (1.24) |
| Benefit magnitude | 3.87 (1.29) | 3.84 (1.35) | 4.04 (1.23) | 4.14 (1.30) | 4.25 (1.11) | 3.98 (1.17) | 4.31 (1.23) |
| Benefit compared to Mytrozen | N/A | N/A | 3.53 (1.44) | 4.12 (1.50) | 3.86 (1.59) | 3.81 (1.52) | N/A |
| Benefit compared to other drugs | 3.67 (1.17) | 3.89 (1.22) | 3.69 (1.15) | 3.77 (1.42) | 3.96 (1.22) | 3.66 (1.22) | 3.96 (1.30) |
| Perceived risk/safety | |||||||
| Side effect likelihood | 3.87 (1.31) | 3.93 (1.19) | 3.74 (1.25) | 3.93 (1.31) | 3.97 (1.12) | 3.89 (1.17) | 3.86 (1.29) |
| Side effect severity | 3.35 (1.11) | 3.37 (1.02) | 3.53 (0.94) | 3.47 (1.00) | 3.60 (1.06) | 3.5 (1.09) | 3.57 (0.91) |
| Safety compared to Mytrozen | N/A | N/A | 3.53 (1.46) | 4.12 (1.45) | 3.82 (1.69) | 3.80 (1.54) | N/A |
| Safety compared to other drugs | 3.67 (1.28) | 4.00 (1.28) | 3.84 (1.18) | 3.79 (1.47) | 3.98 (1.26) | 3.71 (1.2) | 4.05 (1.38) |
| Attitudes toward the biosimilar drug | 4.27 (1.31) | 4.39 (1.18) | 4.33 (1.20) | 4.37 (1.24) | 4.69 (1.16) | 4.38 (1.18) | 4.55 (1.24) |
| Intention to take biosimilar drug | 4.07 (1.53) | 3.98 (1.45) | 3.90 (1.43) | 3.93 (1.47) | 4.32 (1.34) | 3.93 (1.42) | 4.18 (1.42) |
Note: All planned comparisons were statistically nonsignificant at the Bonferonni adjusted levels. Items measured on a 1-6 Likert sale where larger values reflect stronger perceptions or agreement.
N/A – comprehension item not assessed for given condition.